

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

Claims 1-23 (Cancelled).

Claim 24 (New): A DNA gene inactivation construct for homologous recombination in the genome of a mammalian cell, comprising at least 100 bp of a sequence homologous with a gene locus of a subunit of an MHC antigen flanking a sequence encoding a selectable marker gene capable of expression in a mammalian cell, wherein the sequence encoding a selectable marker gene is downstream from a sequence encoding a leader sequence and is fused in frame to a transmembrane coding region of the subunit of the MHC antigen, wherein upon homologous recombination, said gene locus is inactivated, and wherein, as a result of homologous recombination, at least one functional MHC antigen is not expressed.

Claim 25 (New): A DNA construct according to claim 24, wherein said MHC antigen is selected from the group consisting of Class I and Class II antigens.

Claim 26 (New): A DNA construct according to claim 24, wherein said subunit of an MHC antigen is β_2 -microglobulin.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

Claim 27 (New): A DNA construct according to claim 24, wherein said selectable marker gene is an antibiotic resistance gene.

Claim 28 (New): A DNA construct according to claim 27, wherein said selectable marker gene is selected from the group consisting of the Neo resistance gene and the hygromycin resistance gene.

Claim 29 (New): A DNA construct, comprising DNA encoding in the 5' to 3' direction,

a region of homology to a target gene,

a foreign promoter/enhancer joined to a first epitope that binds to a ligand for detection,

a selectable marker gene, and

a second region of homology to said target gene,

said target gene encoding a gene product having a second epitope, and said target gene being selected from the group consisting of a gene encoding a subunit of an MHC antigen and a gene encoding a protein that upregulates expression of MHC antigens,

wherein, upon homologous recombination of said DNA construct into a genome, a recombinant, secreted fusion protein comprising said first epitope that binds to a ligand for detection and said second epitope is expressed in targeted cells, and

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

wherein, as a result of homologous recombination, at least one functional MHC antigen or protein associated with expression of MHC antigens is not expressed.

Claim 30 (New): A DNA construct according to claim 29, wherein said first epitope is CD4.

Claim 31 (New): A DNA construct comprising DNA encoding a transcriptionally and translationally impaired positive selectable marker gene fused in frame to the transmembrane coding region of an integral membrane protein receptor for a cytokine that upregulates the expression of MHC antigen;

wherein the expression product of said DNA is a fusion protein comprising a functional selectable marker expressed on the cytoplasmic side of said membrane.

Claim 32 (New): A DNA construct according to claim 31, wherein said integral membrane protein is IFNyR and said selectable marker gene is the neomycin resistance gene.

Claim 33 (New): A DNA construct according to claim 29, wherein said target gene is selected from the group consisting of genes encoding MHC antigen subunits, T cell receptor subunits, interferon receptors, neurotransmitter receptors, growth factor receptors, IL-1R, TAP 1, TAP 2, β_2 -microglobulin, proteosome subunits and colony stimulating factor receptors.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

Claim 34 (New): A DNA construct according to claim 33, wherein said target gene encodes β_2 -microglobulin.

Claim 35 (New): A DNA construct according to claim 31, wherein said integral membrane protein is selected from the group consisting of interferon receptors, IL-1R, and colony stimulating factor receptors.

Claim 36 (New): A DNA construct comprising DNA encoding a transcriptionally and translationally impaired positive selectable marker gene fused downstream and in frame to the transmembrane coding region of an integral membrane protein that upregulates MHC antigen expression, wherein the expression product of said DNA construct is a fusion protein comprising a functional, selectable marker.

Claim 37 (New): The DNA construct of claim 36, wherein said integral membrane protein is selected from the group consisting of MHC antigen subunits T cell receptor subunits, neurotransmitter receptors, growth factor receptors, TAP1, TAP2, β_2 -microglobulin and proteosome subunits.

Claim 38 (New): A DNA gene inactivation construct for homologous recombination in the genome of a mammalian cell, comprising a first sequence homologous with a gene locus present in the genome of the mammalian cell, having a length of at least 150 base pairs, and flanking a sequence encoding a selectable marker gene capable of expression in the mammalian cell, wherein the sequence encoding the

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

selectable marker gene is downstream from a sequence encoding a leader sequence and is fused in frame to a coding sequence encoding an expression product, wherein the leader sequence comprises a second sequence homologous with the gene locus present in the genome of the mammalian cell and having a length of at least 150 base pairs, wherein upon homologous recombination said gene locus is inactivated, and wherein, as a result of homologous recombination, at least one functional expression product encoded by said gene locus is not expressed.

Claim 39 (New): A DNA construct according to claim 38, wherein said selectable marker gene is the Neo resistance gene.

Claim 40 (New): A DNA construct according to claim 38, wherein said gene locus present in the genome of the mammalian cell is a receptor, and the coding sequence encoding an expression product encodes part or all of the receptor or a modified version of the receptor.

Claim 41 (New): A DNA construct according to claim 40, wherein the receptor is a receptor for an infectious or toxic agent.

Claim 42 (New): A DNA construct according to claim 40, wherein the receptor is a retinoic acid receptor.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

Claim 43 (New): A DNA construct according to claim 40, wherein the receptor is a 3- β adrenergic receptor.

Claim 44 (New): A DNA construct according to claim 40, wherein the receptor is an HIV receptor.

Claim 45 (New): A DNA gene inactivation construct for homologous recombination in the genome of a mammalian cell having a recipient DNA sequence, wherein said recipient DNA sequence comprises complementing DNA comprising a first nucleotide sequence and a second nucleotide sequence downstream of said first nucleotide sequence, wherein the DNA gene inactivation construct comprises:

- (1) a third nucleotide sequence homologous to said first nucleotide sequence;
- (2) a fourth nucleotide sequence homologous to said second nucleotide sequence; and
- (3) a DNA sequence heterologous with respect to said recipient DNA sequence, wherein said heterologous DNA sequence is between said third and said fourth nucleotide sequences and said heterologous DNA sequence comprises a first insertion DNA sequence and a second insertion DNA sequence, wherein said first insertion DNA sequence comprises a first coding sequence that encodes a first product that does not confer resistance to a selection agent involved in the selection of transformants, and said second insertion DNA sequence comprises a second coding sequence that encodes a second product

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

that confers resistance to a selection agent involved in the selection of transformants, wherein upon insertion of said heterologous DNA sequence between said first and said second nucleotide sequences in said recipient DNA sequence by homologous recombination with said third and said fourth nucleotide sequences, to thereby provide a mammalian cell containing the recombinant DNA sequence, said second coding sequence is operably linked to a regulatory sequence allowing the expression of said second product in said mammalian cell.

Claim 46 (New): A DNA construct according to claim 45, wherein said selection agent is neomycin.

Claim 47 (New): A DNA construct according to claim 45, wherein said recipient DNA sequence in the genome of a mammalian cell is a receptor, and wherein the first product that does not confer resistance to a selection agent involved in the selection of transformants is part or all of the receptor or a modified version of the receptor.

Claim 48 (New): A DNA construct according to claim 47, wherein the receptor is a receptor for an infectious or toxic agent.

Claim 49 (New): A DNA construct according to claim 47, wherein the receptor is a retinoic acid receptor.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

Claim 50 (New): A DNA construct according to claim 47, wherein the receptor is a 3-β adrenergic receptor.

Claim 51 (New): A DNA construct according to claim 47, wherein the receptor is an HIV receptor.

Claim 52 (New): A DNA construct, comprising DNA encoding in the 5' to 3' direction,

a region of homology to a target gene,
a foreign promoter/enhancer joined to a first coding sequence that encodes a first gene product,

a selectable marker gene, and
a second region of homology to said target gene,
said target gene comprising a second coding sequence encoding a second gene product,

wherein, upon homologous recombination of said DNA construct into a genome, a recombinant, fusion protein comprising said first gene product and part or all of said second gene product is expressed in targeted cells, and wherein, as a result of homologous recombination, at least one functional copy of the target gene is not expressed.

Claim 53 (New): A DNA construct according to claim 52, wherein the selectable marker gene encodes resistance to neomycin.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

Claim 54 (New): A DNA construct according to claim 52, wherein the first gene product is part or all of a receptor.

Claim 55 (New): A DNA construct according to claim 54, wherein the receptor is a receptor for an infectious or toxic agent.

Claim 56 (New): A DNA construct according to claim 54, wherein the receptor is a retinoic acid receptor.

Claim 57 (New): A DNA construct according to claim 54, wherein the receptor is a 3-β adrenergic receptor.

Claim 58 (New): A DNA construct according to claim 54, wherein the receptor is an HIV receptor.

Claim 59 (New): A DNA construct according to claim 52, wherein the first gene product is part or all of an interferon.

Claim 60 (New): A DNA construct according to claim 52, wherein the first gene product is part or all of an interleukin.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

Claim 61 (New): A DNA construct according to claim 52, wherein the target gene is part or all of a receptor.

Claim 62 (New): A DNA construct according to claim 61, wherein the receptor is a receptor for an infectious or toxic agent.

Claim 63 (New): A DNA construct according to claim 61, wherein the receptor is a retinoic acid receptor.

Claim 64 (New): A DNA construct according to claim 61, wherein the receptor is a 3- β adrenergic receptor.

Claim 65 (New): A DNA construct according to claim 61, wherein the receptor is an HIV receptor.

Claim 66 (New): A DNA construct according to claim 52, wherein the target gene is part or all of an interferon.

Claim 67 (New): A DNA construct according to claim 52, wherein the target gene is part or all of an interleukin.

Claim 68 (New): A DNA construct comprising a first DNA sequence and a second DNA sequence, wherein said first DNA sequence comprises a first coding

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

sequence that encodes a first gene product that does not confer resistance to a selection agent involved in the selection of transformants, and said second DNA sequence comprises a second coding sequence that encodes a second gene product that confers resistance to a selection agent involved in the selection of transformants, wherein the second DNA sequence is downstream of the first DNA sequence, wherein the expression product of said DNA construct comprises the second product that confers resistance to a selection agent involved in the selection of transformants, in functional form.

Claim 69 (New): A DNA construct according to claim 68, wherein the selective agent is neomycin.

Claim 70 (New): A DNA construct according to claim 68, wherein the expression product of said DNA construct localizes in the cytoplasm when expressed in a mammalian cell.

Claim 71 (New): A DNA construct according to claim 68, wherein the first gene product is part or all of a receptor.

Claim 72 (New): A DNA construct according to claim 71, wherein the receptor is a receptor for an infectious or toxic agent.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

Claim 73 (New): A DNA construct according to claim 71, wherein the receptor is a retinoic acid receptor.

Claim 74 (New): A DNA construct according to claim 71, wherein the receptor is a 3- β adrenergic receptor.

Claim 75 (New): A DNA construct according to claim 71, wherein the receptor is an HIV receptor.

Claim 76 (New): A DNA construct according to claim 68, wherein the first gene product is part or all of an interferon.

Claim 77 (New): A DNA construct according to claim 68, wherein the first gene product is part or all of an interleukin.

Claim 78 (New): A DNA gene inactivation construct for homologous recombination in the genome of a mammalian cell, comprising a first sequence homologous with a gene locus present in the genome of the mammalian cell, having a length of at least 150 base pairs, and flanking a sequence encoding a selectable marker gene capable of expression in the mammalian cell, wherein the sequence encoding the selectable marker gene is downstream from a sequence encoding a leader sequence and is fused in frame to a coding sequence encoding an expression product, wherein the expression product of said DNA construct localizes to the cytoplasm when

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

expressed in a mammalian cell, wherein the leader sequence comprises a second sequence homologous with the gene locus present in the genome of the mammalian cell and having a length of at least 150 base pairs, wherein upon homologous recombination said gene locus is inactivated, and wherein, as a result of homologous recombination, at least one functional expression product encoded by said gene locus is not expressed.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com